Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology... IntroductionGastroenteropancreatic neuroendocrine tumors (GEP-NETs) can result in symptoms such as diarrhea, flushing, abdominal pain, and fatigue and are often associated with a significant disease burden and poor prognosis. This non-interventional, prospective, observational study evaluated the real-world safety and effectiveness of lanreotide depot, a somatostatin analog (SSA) used to treat GEP-NETs, in a community setting.MethodsIn this prospective, non-interventional study (NCT02730104), adult patients with locally advanced (inoperable), metastatic GEP-NETs treated with lanreotide depot were evaluated by their physician every 6 months from enrollment for 24 months. Clinically defined time to disease progression (TTDP) and overall survival (OS) were estimated for the total population and by primary tumor type (gastrointestinal [GI], pancreatic, unknown origin), and an exploratory analysis determined the rate of progression-free survival (PFS) at 12 and 24 months. Patient satisfaction was evaluated via the Treatment Satisfaction Questionnaire for Medication (TSQM-9), and safety information was recorded.ResultsOf 99 patients, the 24-month PFS rate was 73.7% (95% confidence interval [CI] 63.1–81.7) and 24-month OS rate was 84.2% (95% CI 74.0–90.7). Median TTDP was not reached because few patients experienced disease progression during the study period. The majority of responding patients expressed satisfaction with treatment on each domain of the TSQM-9. Treatment-related adverse events (AEs) occurred in 19.2% of patients, while no serious AEs (SAEs) were related to the study drug.ConclusionsLanreotide depot is an effective and well-tolerated treatment for GEP-NETs in the real-world community setting.Trial registrationClinicalTrials.gov identifier, NCT02730104. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study

Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/lanreotide-depot-to-treat-gastroenteropancreatic-neuroendocrine-tumors-dvbVSBhKts
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2022
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-022-00208-1
Publisher site
See Article on Publisher Site

Abstract

IntroductionGastroenteropancreatic neuroendocrine tumors (GEP-NETs) can result in symptoms such as diarrhea, flushing, abdominal pain, and fatigue and are often associated with a significant disease burden and poor prognosis. This non-interventional, prospective, observational study evaluated the real-world safety and effectiveness of lanreotide depot, a somatostatin analog (SSA) used to treat GEP-NETs, in a community setting.MethodsIn this prospective, non-interventional study (NCT02730104), adult patients with locally advanced (inoperable), metastatic GEP-NETs treated with lanreotide depot were evaluated by their physician every 6 months from enrollment for 24 months. Clinically defined time to disease progression (TTDP) and overall survival (OS) were estimated for the total population and by primary tumor type (gastrointestinal [GI], pancreatic, unknown origin), and an exploratory analysis determined the rate of progression-free survival (PFS) at 12 and 24 months. Patient satisfaction was evaluated via the Treatment Satisfaction Questionnaire for Medication (TSQM-9), and safety information was recorded.ResultsOf 99 patients, the 24-month PFS rate was 73.7% (95% confidence interval [CI] 63.1–81.7) and 24-month OS rate was 84.2% (95% CI 74.0–90.7). Median TTDP was not reached because few patients experienced disease progression during the study period. The majority of responding patients expressed satisfaction with treatment on each domain of the TSQM-9. Treatment-related adverse events (AEs) occurred in 19.2% of patients, while no serious AEs (SAEs) were related to the study drug.ConclusionsLanreotide depot is an effective and well-tolerated treatment for GEP-NETs in the real-world community setting.Trial registrationClinicalTrials.gov identifier, NCT02730104.

Journal

Oncology and Therapy – Springer Journals

Published: Dec 1, 2022

Keywords: GEP-NETs; Lanreotide depot; Neuroendocrine tumors; Oncology; Progression-free survival; Patient satisfaction; Prospective study; Real-world evidence

References

  • Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
    Dasari, A; Shen, C; Halperin, D
  • Neuroendocrine and adrenal tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
    Shah, MH; Goldner, WS; Benson, AB
  • Neuroendocrine tumor disease: an evolving landscape
    Frilling, A; Akerström, G; Falconi, M
  • Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions
    Deroose, CM; Hindié, E; Kebebew, E
  • Management of functional neuroendocrine tumors of the pancreas
    Öberg, K
  • Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study
    Strosberg, JR; Benson, AB; Huynh, L
  • Patient-reported experience of diagnosis, management, and burden of neuroendocrine tumors: results from a large patient survey in the United States
    Wolin, EM; Leyden, J; Goldstein, G; Kolarova, T; Hollander, R; Warner, RRP
  • Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging
    Kim, KW; Krajewski, KM; Nishino, M
  • Nothing but NET: a review of neuroendocrine tumors and carcinomas
    Oronsky, B; Ma, PC; Morgensztern, D; Carter, CA
  • Principles of diagnosis and management of neuroendocrine tumours
    Raphael, MJ; Chan, DL; Law, C; Singh, S
  • Delays and routes to diagnosis of neuroendocrine tumours
    Basuroy, R; Bouvier, C; Ramage, JK; Sissons, M; Srirajaskanthan, R
  • Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)
    Garcia-Carbonero, R; Capdevila, J; Crespo-Herrero, G
  • Lanreotide in metastatic enteropancreatic neuroendocrine tumors
    Caplin, ME; Pavel, M; Ćwikła, JB
  • Patterns of care among real-world patients with metastatic neuroendocrine tumors
    Klink, AJ; Feinberg, B; Yu, HT
  • Analysis of real-world treatment patterns, healthcare resource utilization, and costs between octreotide and lanreotide among patients with neuroendocrine tumors
    Huynh, L; Cai, B; Cheng, M
  • Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications
    Bharmal, M; Payne, K; Atkinson, MJ; Desrosiers, M-P; Morisky, DE; Gemmen, E
  • Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: a prospective observational study from a single institute
    Jun, E; Kim, SC; Song, KB
  • Observational study to assess quality of life in patients with pancreatic neuroendocrine tumors receiving treatment with everolimus: the OBLIQUE Study (UK Phase IV Trial)
    Ramage, JK; Punia, P; Faluyi, O
  • Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors
    Palazzo, M; Lombard-Bohas, C; Cadiot, G
  • Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)
    Khan, MS; El-Khouly, F; Davies, P; Toumpanakis, C; Caplin, ME
  • Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters
    Faggiano, A; Modica, R; Lo Calzo, F
  • Therapeutic sequences in patients with grade 1–2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group
    Faggiano, A; Di Maio, S; Mocerino, C
  • Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
    Caplin, ME; Pavel, M; Phan, AT
  • Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
    Pavel, M; Ćwikła, JB; Lombard-Bohas, C
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer, EA; Therasse, P; Bogaerts, J
  • Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
    Kulke, MH; Siu, LL; Tepper, JE
  • Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
    Rinke, A; Müller, HH; Schade-Brittinger, C
  • Everolimus for advanced pancreatic neuroendocrine tumors
    Yao, JC; Shah, MH; Ito, T
  • Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
    Faivre, S; Niccoli, P; Castellano, D
  • Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial
    Vinik, AI; Wolin, EM; Liyanage, N; Gomez-Panzani, E; Fisher, GA
  • The antiproliferative role of lanreotide in controlling growth of neuroendocrine tumors: a systematic review
    Michael, M; Garcia-Carbonero, R; Weber, MM; Lombard-Bohas, C; Toumpanakis, C; Hicks, RJ
  • Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
    Aparicio, T; Ducreux, M; Baudin, E
  • Living with neuroendocrine tumors: assessment of quality of life through a mobile application
    Adams, JR; Ray, D; Willmon, R; Pulgar, S; Dasari, A
  • Patient experience with somatostatin analog treatments for neuroendocrine tumors: insight from qualitative interviews
    Seo, C; Horodniceanu, E; Shah, R
  • Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: a survey study
    Halperin, DM; Huynh, L; Beaumont, JL
  • Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: an observational time and motion analysis
    Ryan, P; McBride, A; Ray, D
  • Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: an international observational study
    Ruszniewski, P; Valle, JW; Lombard-Bohas, C
  • A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence
    Barbosa, CD; Balp, M-M; Kulich, K; Germain, N; Rofail, D
  • Medication adherence: WHO cares?
    Brown, MT; Bussell, JK
  • Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Pavel, M; Öberg, K; Falconi, M
  • Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
    Díez, M; Teulé, A; Salazar, R
  • 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET
    Ambrosini, V; Campana, D; Tomassetti, P; Fanti, S
  • Diagnostic approaches to neuroendocrine neoplasms of unknown primary site
    Berner, AM; Pipinikas, C; Ryan, A
  • Capecitabine and temozolomide in neuroendocrine tumor of unknown primary
    Chauhan, A; Farooqui, Z; Murray, LA